Series A: e-Books on Cardiovascular Diseases
Series A Content Consultant: Justin D Pearlman, MD, PhD, FACC
VOLUME FOUR
Regenerative and Translational Medicine
The Therapeutic Promise for
Cardiovascular Diseases
Larry H Bernstein, MD, FCAP, Senior Editor, Author and Curator
and
Aviva Lev-Ari, PhD, RN, Editor and Curator
Aviva Lev-Ari, PhD, RN
Stem Cells and Cardiac Repair: Content Curation & Scientific Reporting
Lev-Ari, A. Stem cells create new heart cells in baby mice, but not in adults, study shows
Lev-Ari, A. Cardiovascular Disease (CVD) and the Role of agent alternatives in endothelial Nitric Oxide Synthase (eNOS) Activation and Nitric Oxide Production
Lev-Ari, A. Bystolic’s generic Nebivolol – positive effect on circulating Endothelial Progenitor Cells endogenous augmentation
Lev-Ari, A. Circulating Endothelial Progenitor Cells Milestones in the research on Circulating Endothelial Progenitor Cells as diagnostic markers of cardiovascular risk have been reported in NEJM
Circulating Endothelial Progenitor Cells Milestones in the research on Circulating Endothelial Progenitor Cells as diagnostic markers of cardiovascular risk have been reported in NEJM 2003 348:593– 600; (2005); Circulating Endothelial Progenitor Cells and Cardiovascular Outcomes, NEJM, 353: 999-1007; Circulating Endothelial Progenitor Cells Correspondence http://www.nejm.org December 15, 2005; (2005) Correspondence to the Editor on Circulating Endothelial Progenitor Cells. NEJM, 353:24, 2613-2616; Werner, N & Nickenig, G. (2005b). Authors Reply to Correspondence to the Editor on Circulating Endothelial Progenitor Cells. NEJM, 353:24, 2613-2616. Rosenzweig A., (2005). Circulating Endothelial Progenitors – Cells as Biomarkers. NEJM., 353;10: 1055-1057.
Based on that state of the art research I defined in 2006 an independent research study and carried out research on “Macrovascular Disease – Therapeutic Potential of cEPCs: Reduction Methods for CV Risk” An Investigation of the Potential of circulating Endothelial Progenitor Cells (cEPCs) as a Therapeutic Target for Pharmacological Therapy Design for Cardiovascular Risk Reduction: A New Multimarker Biomarker Discovery. I’ll attribute my increasing interest in Molecular Cardiology to above NEJM articles.
http://www.nejm.org/doi/full/10.1056/NEJMp1112812#t=comments
Lev-Ari, A. Macrovascular Disease – Therapeutic Potential of cEPCs: Reduction Methods for CV Risk
Lev-Ari, A. Heart patients’ skin cells turned into healthy heart muscle cells
Lev-Ari, A. Resident-cell-based Therapy in Human Ischaemic Heart Disease: Evolution in the PROMISE of Thymosin beta4 for Cardiac Repair
http://pharmaceuticalintelligence.com/2012/04/30/93/
Articles commissioned by Dr. Lev-Ari for http://pharmaceuticalintelligence.com
Larry H Bernstein, MD, FCAP
Progenitor Cell Transplant for MI and Cardiogenesis (Part 1)
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Source of Stem Cells to Ameliorate Damage Myocardium (Part 2)
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
An Acellular 3-Dimensional Collagen Scaffold Induces Neo-angiogenesis (Part 3)
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Jmjd3 and Cardiovascular Differentiation of Embryonic Stem Cells
Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Stem Cell Therapy for Coronary Artery Disease (CAD)
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
http://pharmaceuticalintelligence.com/2013/11/02/stem-cell-therapy-for-coronary-heart-disease/
Intracoronary Transplantation of Progenitor Cells after Acute MI
Curators: Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
http://pharmaceuticalintelligence.com/2013/11/02/progenitor-cells-coronary-graft-after-ami/
Sudipta Saha, PhD
Saha, S. Innovations in Bio-instrumentation for Measurement of Circulating Progenitor Endothelial Cells in Human Blood
Saha, S. Human Embryonic-Derived Cardiac Progenitor Cells for Myocardial Repair
Saha, S. Endothelial Differentiation and Morphogenesis of Cardiac Precursors
Ritu Saxena, PhD
In focus: Circulating Tumor Cells
http://pharmaceuticalintelligence.com/2013/06/24/in-focus-circulating-tumor-cells/
In Focus: Targeting of Cancer Stem Cells
http://pharmaceuticalintelligence.com/2013/03/27/in-focus-targeting-of-cancer-stem-cells/
Mitochondrial Dynamics and Cardiovascular Disease
http://pharmaceuticalintelligence.com/2012/11/14/mitochondrial-dynamics-and-cardiovascular-diseases/
Blood-vessels-generating stem cells discovered
http://pharmaceuticalintelligence.com/2012/10/22/blood-vessel-generating-stem-cells-discovered/
Mitochondria: More than just the “powerhouse of the cell”
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.